These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3100426)

  • 21. [Characterization of imipenem resistance in Pseudomonas aeruginosa: decreased phenotypic expression of outer membrane proteins D1 and D2].
    Cullmann W; Büscher KH; Opferkuch W
    Immun Infekt; 1986 Nov; 14(6):227-9. PubMed ID: 3100427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens.
    Giamarellou H; Sfikakis P; Voutsinas D; Galanakis N; Daikos GK
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():175-9. PubMed ID: 3469191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns.
    Troillet N; Samore MH; Carmeli Y
    Clin Infect Dis; 1997 Nov; 25(5):1094-8. PubMed ID: 9402364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis.
    Krilov LR; Blumer JL; Stern RC; Hartstein AI; Iglewski BN; Goldmann DA
    Rev Infect Dis; 1985; 7 Suppl 3():S482-9. PubMed ID: 3901211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem.
    Hostacká A; Karelová E
    Microbios; 1997; 90(362):45-50. PubMed ID: 9301070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imipenem/cilastatin: the first carbapenem antibiotic.
    Lyon JA
    Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.
    Krcméry V; Trupl J; Kunová A; Spánik S; Ilavská I; Hel'pianska L; Bezáková I; Drgona L; Oravcová E; Studená M; Lacka J; Sevcíková L; Koren P; Kukucková E; Stopková K; Krupová I; Grausová S; Svec J
    Bratisl Lek Listy; 1996 Nov; 97(11):647-51. PubMed ID: 9117427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A clinical evaluation of MK-0787/MK-0791 for long-term administration in urological infections].
    Suzuki K; Takanashi K; Naide Y; Fujita T; Ogawa T; Hirabayashi S; Tamai H; Yanaoka M; Ishiguro K; Asano H
    Hinyokika Kiyo; 1986 Sep; 32(9):1387-408. PubMed ID: 3101448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa-acquired resistance to imipenem-cilastatin: commentary on clinical implications of antibiotic resistance.
    Tidwell BH; Cleary JD
    Pharmacotherapy; 1993; 13(2):165; discussion 166. PubMed ID: 8469624
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
    Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
    Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem.
    Miró E; Navarro F; March F; Sanchez F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 1995 Aug; 14(8):731-2. PubMed ID: 8566000
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of moderate or severe infections using imipenem/cilastatin. 41 cases based on a multicenter protocol].
    Stahl JP; Chavanet P; Robert D; Croize J; Mercatello A; Bru JP; Aguilaniu F; Portier H; Micoud M
    Pathol Biol (Paris); 1986 May; 34(5):465-9. PubMed ID: 3534723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials.
    Calandra GB; Ricci FM; Wang C; Brown KR
    J Clin Pharmacol; 1988 Feb; 28(2):120-7. PubMed ID: 3283176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospital acquired native valve endocarditis caused by Acinetobacter calcoaceticus and treated with imipenem/cilastin.
    Cumberland NS; Jones KP
    J R Army Med Corps; 1987 Oct; 133(3):156-8. PubMed ID: 3479562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections.
    Trumbore D; Pontzer R; Levison ME; Kaye D; Cynamon M; Liu C; Hinthorn DR; Tan JS; File TM
    Rev Infect Dis; 1985; 7 Suppl 3():S476-81. PubMed ID: 3931198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipenem/cilastatin therapy for serious infections in neonates and infants.
    Nalin DR; Jacobsen CA
    Scand J Infect Dis Suppl; 1987; 52():46-55. PubMed ID: 3331042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, comparative trial of imipenem/cilastatin and moxalactam in the treatment of serious obstetric and gynecologic infections.
    Berkeley AS; Freedman KS; Hirsch JC; Ledger WJ
    Surg Gynecol Obstet; 1986 Mar; 162(3):204-8. PubMed ID: 3513346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imipenem/cilastatin as secondary therapy for infections in cancer patients.
    Bodey GP; Rolston K; Jones P; Alvarez ME; Fainstein V; Steelhammer L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():161-6. PubMed ID: 3469189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.